"According to a letter the drugmaker sent to Parent Project Muscular Dystrophy, a patient advocacy group.....In its letter, Pfizer estimated those mutations cover around 15% of the treatable patient population with DMD, a rare muscle-wasting caused by an abnormal production of the dystrophin protein. Pfizer said three cases of muscle weakness, two of which included heart inflammation, forced the trial amendment. ..."
So, another devastating news to the DMD patients?
You would have thought Pat Furlong from PPMD is very pleased with our recent results then... and I hope it is from despair to delight.... No only our drug has positive effect on muscle function and strength but also against loss of ambulation in DMD and also providing 1-2 years delayed loss of ambulation....life matter, that's what count....
"According to a letter the drugmaker sent to Parent Project...
-
- There are more pages in this discussion • 722 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $94.66M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 9.8¢ | $58.09K | 574.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 38503 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 194063 | 5 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |